Terns Pharmaceuticals, Inc.
TERN
$3.18
-$0.27-7.83%
| Weiss Ratings | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.08 | |||
| Price History | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.40% | |||
| 30-Day Total Return | -31.47% | |||
| 60-Day Total Return | -52.75% | |||
| 90-Day Total Return | -53.64% | |||
| Year to Date Total Return | -43.92% | |||
| 1-Year Total Return | -52.61% | |||
| 2-Year Total Return | -67.05% | |||
| 3-Year Total Return | 6.00% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -69.74% | |||
| 52-Week Low % Change | 6.48% | |||
| Price | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.40 | |||
| 52-Week Low Price | $3.24 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Sep 10, 2024 | |||
| Valuation | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 293.04M | |||
| Enterprise Value | -78.43M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.18 | |||
| Earnings Per Share Growth | -6.81% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.80 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.18 | |||
| Enterprise Value/EBITDA (TTM) | 0.79 | |||
| Enterprise Value/EBIT | 0.78 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 77.82M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 525 5535 | |||
| Address | 1065 East Hillsdale Boulevard Foster City, CA 94404 | |||
| Website | www.ternspharma.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.23% | |||
| Return on Equity | -- | |||
| Income Statement | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -99.66M | |||
| EBIT (TTM) | -99.98M | |||
| Net Income (TTM) | -88.07M | |||
| Net Income Avl. to Common (TTM) | -88.07M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 26.28% | |||
| EPS Diluted (TTM) | -1.18 | |||
| EPS Diluted Growth (Q YOY) | 32.23% | |||
| Balance Sheet | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 372.78M | |||
| Cash Per Share (Q) | $4.79 | |||
| Total Current Assets (Q) | 376.51M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 364.47M | |||
| Current Ratio (Q) | 32.992 | |||
| Book Value Per Share (Q) | $4.29 | |||
| Total Assets (Q) | 378.23M | |||
| Total Current Liabilities (Q) | 11.41M | |||
| Total Debt (Q) | 1.31M | |||
| Total Liabilities (Q) | 13.76M | |||
| Total Common Equity (Q) | 364.47M | |||
| Cash Flow | TERN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 129.17M | |||
| Cash from Financing (TTM) | 177.55M | |||
| Net Change in Cash (TTM) | 232.24M | |||
| Levered Free Cash Flow (TTM) | -45.90M | |||
| Cash from Operations (TTM) | -74.75M | |||
